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The gut microbiota makes up the majority of the human bacterial population, and although the gut microbiota
resides in the intestines, it is able to exert systemic effects. Therefore, many diseases and conditions could be
impacted by the gut microbiota when its composition is imbalanced, otherwise known as dysbiosis. However, apart
from understanding the illnesses, we must also try to understand the intestinal flora itself to move forward and
develop potential treatments.Review
Introduction
Although the word “bacteria” is frequently associated
with negative connotations of infection and disease, there
is in fact an abundance of bacteria that is beneficial for the
human body. These certain bacteria are microbiota, which
have a commensal relationship with the body—the body
gives the bacteria a place to flourish, and in return, the
bacteria offer protection and help with regulation. The en-
tire human microbiota has a total of 1014 bacterial cells,
which is 10 times the number of human cells in the body
[1]. Some examples of the locations of microbiota include
the skin, the vagina, the oral cavity, but most prominently,
the intestines, where gut microbiota reside.
Gut microbiota comprises approximately 70% of the
entire microbiota population, and is dominated by the
Bacteroidetes and Firmicutes phyla. Other phyla that
exist in gut microbiota in smaller quantities include Pro-
teobacteria, Verrucomicrobia, Actinobacteria, Fusobac-
teria, and Cyanobacteria [2]. Gut microbiota aids in
food digestion and also helps with the production of
some vitamins like vitamins B and K, which are essential
towards cell metabolism and blood coagulation by modify-
ing proteins to allow binding to calcium ions. Furthermore,
gut microbiota can combat harmful microorganisms by
creating a barrier effect in the immune system. The im-
portance of acquiring microbiota has been emphasized in
studies with germ-free animals, where it was found that* Correspondence: jamesli@hku.hk
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unless otherwise stated.commensal organisms are required for the development of
a fully functional immune system [3]. Babies delivered by
Cesarean section are at higher risk for immune-mediated
diseases because they did not undergo initial microbial
colonization from the vaginal canal [4]. The microbiota
not only plays a role in the local intestinal immune system,
but also in systemic immune responses [5].
Changes in microbiota diversity and balance can lead
to physiological changes that are not restricted to the
gastrointestinal system. One of the modes by which gut
microbiota impacts other parts of the body is controlled
by intestinal permeability. Pathogen overgrowth and cer-
tain models of stress promote the loss of the intestinal
barrier, thus increasing intestinal permeability, allowing
for gut microbiota to travel across the intestinal epithe-
lium and into systemic circulation. This phenomenon is
often referred to as “leaky gut” syndrome, and it enables
gut microbiota to impact the entire body and immune
system [6]. Therefore, a healthy balance of gut micro-
biota is crucial not only for proper digestive functioning,
but also for a strong immune system. It follows that
imbalances and dysregulation of gut microbiota can
lead to a host of different diseases. Some different types
include autoimmune, hyper-immune, cardiovascular,
chronic, neurological, cancerous, psychiatric diseases,
and many more.
This review will cover some of the diseases related to
microbiotal dysbiosis, as well as highlight ways that can
be used to further expand our current knowledge. Fur-
thermore, this review will consider the modification of
gut microbiota in the body to help counter microbial
imbalance, and potentially act as a form of treatment.s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Autoimmune
An example of an autoimmune disease influenced by gut
microbiota is Type 1 diabetes (T1DM), or juvenile dia-
betes. Studies comparing germ-free and gnotobiotic
(populated with specific microbes) mice have revealed
that T1DM is among the diseases affected by reduced
numbers of commensal bacteria [7], especially low num-
bers of butyrate-producing bacteria such as those from
the Firmicutes phylum, leading to an altered ratio be-
tween Bacteroidetes and Firmicutes bacteria [8]. The im-
balance between these two dominant phyla could lead to
more physiological problems for the patients. A study
has also shown that diabetic patients younger than
2.9 years have less bacteria from Clostridial clusters IV
and XIVa, which also produce butyrate, hence corrobor-
ating data from the mice studies [6].
Inflammatory bowel disease (IBD) is a gastrointestinal
disorder also due to autoimmune dysregulation. IBD is a
spectrum of chronic diseases marked by recurring in-
flammation of the intestinal mucosal lining. Two main
phenotypes of IBD are Crohn’s disease (CD) and ulcera-
tive colitis (UC), and both have been shown to be linked
to gut microbiota dysbiosis. Various studies claim that
IBD exhibits significant decrease in microbial diversity,
increased bacterial count, and increase in detrimental
bacteria [9]. Studies indicate that UC is characterized by
a decline in Firmicutes and Bacteroidetes, like in T1DM,
and an unusual increase in Proteobacteria. Also like
T1DM, UC has also been associated with a loss of bac-
teria from butyrate-producing Clostridial cluster XIVa
[10]. In CD, the disease was mainly observed in areas
containing the highest concentrations of bacteria [11].
Furthermore, a metabonomic study by Bjerrum et al. has
shown that while UC is marked by a decrease in Clos-
tridial coccoides of Clostridial cluster XIVa, CD showed
a decrease in Faecalibacterium prausnitzii. Interestingly,
both C. coccoides and F. prausnitzii are important in the
formation of short chain fatty acids, which includes bu-
tyrate. Although decreased butyrate stems from these
specific bacterial deficiencies, decreased butyrate in itself
can perpetuate the cycle of chronic inflammation and
microbiotal dysbiosis in UC and CD. Therefore, these
two phenotypes of IBD ultimately both end in dysbiosis
even with decrease- in different species of bacteria.
There has also been interest shown in the link between
genetics, microbiota, and IBD. In one study, the micro-
biota of siblings of CD patients were studied and com-
pared to the patients’ microbiota. It was shown that
siblings of CD patients have a higher risk of developing
CD and, like the CD patients, show signs of fecal dysbio-
sis [12]. Furthermore, since CD is caused by interactions
between genetic and environmental factors, gut micro-
biota plays a role in the disease. The study confirmedmicrobiota alterations in CD patients, for example re-
duction in diversity, decrease in Ruminococcaceae, and
increase in Enterbacteriaceae [13].
Dysbiosis is also related to the development of CD and
UC in children, which becomes readily apparent when
looking at the methods used to treat pediatric IBD. One
commonly used treatment for pediatric CD is exclusive
enteral nutrition (EEN)—the total replacement of nor-
mal diet with liquid diet/ formula during the duration of
treatment. Seeing as gut flora can be affected by envir-
onmental factors such as diet, the effectiveness of EEN
suggests a relationship between microbiotal dysbiosis
and the development of CD.
Other autoimmune conditions such as allergies have
also been shown to be influenced by gut microbiota. Low
microbial diversity has been observed to precede allergic
diseases [14]. A possible explanation for the low microbial
diversity is linked to the hygiene hypothesis of allergy. In
the context of microbiota, the hypothesis suggests that ex-
cessively hygienic practices impede the development of a
diverse and balanced gut microflora in infants, resulting in
irregular immune development and hence the emergence
of allergic disease.
Two longitudinal studies by Azad et al. point towards
a relationship between gut microbiota and the hygiene
hypothesis. The first study looked at the influence of
pets and siblings on microbiota composition and diver-
sity and found that microbiota richness and diversity
was increased in infants living with pets, but decreased
in those living with older siblings, particular in relation
to levels of Bifidobacteriaceae and Peptostreptococcaceae.
The second study investigated food sensitization and gut
microbiota, and found that low gut microbiota richness
paired with an increased ratio between Enterobacteria-
ceae and Bacteroidaceae are linked to food sensitization.
Thus, gut microflora composition in infants coupled
with the hygiene hypothesis seems to be a reasonable
connection.
Psychiatric
There is known to be bidirectional communication be-
tween the gut and the brain in the gut-brain axis. Estab-
lished pathways of communication between the gut and
the brain include the autonomic nervous system (ANS)
and the enteric nervous system (ENS) [15]. In addition,
there has been increasing interest in the microbiota-gut-
brain axis ever since the observation that oral antibiotics
and laxatives improved cases of hepatic encephalopathy
[16]. The microbiota-gut-brain axis is also a point of
interest for its role in both inducing and treating psychi-
atric stress-related conditions such as depression and
anxiety.
Stress is chiefly monitored by the hypothalamic-pituitary-
adrenal (HPA) axis. Depression and anxiety have both been
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corticotropin-releasing factor (CRF), and in turn, adre-
nocorticotropic hormone (ACTH) in the presence of
stress [17]. This relates to gut microbiota because stress
is known to increase intestinal permeability, allowing
bacteria to travel across the intestinal mucosa and
interact with the nervous system. In fact, a 2004 report
established a direct link between microbiota and the
HPA axis [15], connecting microbiota with depression
and anxiety. This link was further supported more re-
cently in April 2014 in a study involving germ-free
(GF) and specific pathogen free (SPF) rats [18]. It was
found that in social experiments, GF rats spent less
time sniffing unknown partners, indicating higher levels
of stress in unfamiliar social situations. Furthermore,
GF rats had higher CRF mRNA expression in the hypo-
thalamus and lower dopaminergic turnover rates in the
frontal cortex, hippocampus, and striatum. However,
the GF rats did not have any sensorimotor differences
from the SPF rats [18], which isolate the impact of gut
microbiota chiefly to the HPA axis. This evidence sup-
ports that an absence, and possibly imbalance, of gut
microbiota impacts behavioral responses to acute
stress, contributing to depression and anxiety.
Besides the connection between gut microbiota and the
brain via the HPA axis, there has been evidence attribut-
ing microbiota-gut-brain communication to the vagus cra-
nial nerve [19,20]. A study involving mice proved that
chronic treatment with lactobacillus rhamnosus altered
GABA mRNA in the brain and reduced stress-induced
corticosteroid, but that these changes were not observed
in vagotomized mice [21]. However, further investigation
should be carried out with regards to this specific pathway
to obtain more definitive knowledge.
In terms of pediatrics, one of the more frequently
studied psychiatric conditions in relation to gut micro-
biota has been autism. It has been noted that autism—a
developmental disorder marked by impaired social inter-
actions and restricted/repetitive behavior—tends to
present with digestive issues. Finegold et al. found that
autistic children have higher counts of Clostridial bac-
teria than control children, including nine species of
Clostridium not found in the controls. In addition, it
was found that autistic children have increased Bacteroi-
detes, and decreased Firmicutes and Bifidobacterium
species. Although correlation does not necessitate maen
causative association, such findings provide new insight
towards the studying of autism.
Cancers
Cancer has a variety of causes, such as genetics, UV ex-
posure, radiation exposure, carcinogens, and diet and
physical activity. It has also been found that gut micro-
biota may be related to the development of some cancers,such as colorectal cancer (CRC). CRC is cancer of the
colon, rectum, and anus in the form of malignant tumors.
Although the development of CRC is influenced by gen-
etic factors such as damaged DNA and genetic instability,
environmental factors that impact the gut microbiota may
also promote CRC development [22]. This has been sup-
ported by mouse models, where fecal microbiota from
CRC patients and healthy individuals were transplanted
into GF mice and induced different levels of tumorigenesis
in the mice. With regards to specific bacterial types in-
volved in the tumorigenesis, gram-negative bacteria had
the highest correlation while gram-positive bacteria such
as Clostridial cluster XIVa were strongly negatively corre-
lated with tumors [23]. Even though the mice were trans-
planted with distinct microbial populations from different
human patients, they all underwent structural changes
and the extent of these changes was related to tumor
incidence. The study concluded that the initial structure
of gut microbiota affects susceptibility to colonic tumori-
genesis [23]. Obesity, another prominent risk factor for
cancer, has been associated with microbiotal dysbiosis,
and could result in physiological changes towards cancer.
Microbial metabolism has also been speculated to be re-
lated to cancer development [24].
Hepatocellular carcinoma (HCC) is another instance of
cancer impacted by gut microbiota. Liver cirrhosis and
HCC are not unusual in end-stage chronic liver disease,
but the molecular mechanisms relating HCC and liver dis-
ease are still not completely clear [25]. However, it was re-
cently discovered that increased translocation of gut
microbiota is characteristic of chronic liver disease [26],
and that gut microbiota may be the main source of portal
vein lipopolysaccharide (LPS), thus promoting tumorigen-
esis [25]—a theory also supported by the earlier example of
a high correlation of gram-negative bacteria in CRC devel-
opment. It has been speculated that LPS from the gram-
negative bacteria promotes hepatocarcinogenesis but does
not actually change the gut microbiota composition [26].
However, there exists some controversy over the effect
of gut microbiota in the early stages of hepatocarcinogen-
esis. Yu et al. found a link between gut microbiota and
TLR4 to tumor initiation. On the other hand, Dapito et al.
concluded that gut microbiota and TLR4 do not have a
role in initiating HCC but rather promote it [26]. Dapito
et al. also found that even though gut sterilization pre-
vented the development of HCC, it did not lead to regres-
sion of already existing tumors. Therefore, although some
information is known about gut microbiota relating to
cancer, much remains to be clarified, particularly in terms
of HCC, before it can be considered conclusive.
Treatments
Using the information known about gut microbiota
imbalances in relation to disease, treatments involving
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illnesses.
Biotics
Probiotics
Probiotics are dietary supplements that contain live bac-
teria to add to and strengthen the already existing gut
microbiota, a common example being lactobacilli in
dairy products such as yoghurt.
Probiotics can be used in a wide variety of diseases re-
lated to microbiota, including depression and anxiety.
As mentioned earlier, a mouse model study investigated
the effects of lactobacillus rhamnosus on GABA, and
showed that chronic treatment with lactobacillus rham-
nosus caused changes in GABA mRNA in the brain and
reduced stress-induced corticosteroid [21]. Other human
studies have also reported that altering gut microbiota
with probiotics may lead to change in brain function
and even in subjective reports of mood [27].
For diabetes, the mechanisms by which anti-diabetic
probiotics function may be related to reduction of oxida-
tive stress and inflammation with modification of gut
microbiota [28]. Probiotics may also affect the enteric
immune system by producing IgA or influencing the re-
lease of anti-inflammatory cytokine. So far, the most
common probiotics suggested for diabetes are lactobacil-
lus and bifidobacterium [28], which may improve the ab-
sorption of antioxidants for protection against damage
by free radicals in the body.
For IBD, probiotics have been shown to be only mildly
effective. Probiotics have some effect in treating UC, but
no such similar results have been found in treating CD.
This could be because CD is a disease made up of many
different factors with varying genetics, phenotypes, and
severity [Guandalini]. On the other hand, UC does not
seem to be as common in family histories. Although CD
and UC are both inflammatory bowel diseases, probio-
tics cannot treat them with equal effectiveness, showing
that changing one parameter may not be enough to cure
the disease. Diet and other environmental components
need to be taken into account. Unless the disease is
completely and undoubtedly caused by microbiotal dys-
biosis alone, probiotics may be useful but the disease
should still be approached holistically.
Although the use of probiotics has been suggested for
many types of diseases, the ideal probiotic strain for each
type has not yet been identified. Furthermore, concrete
data regarding the safety of probiotic usage is still not en-
tirely sufficient [29]. These two areas should be improved
upon to make the usage of probiotics a more effective.
Prebiotics
Unlike probiotics, prebiotics are not live preparations,
but instead are food ingredients that may be fermentedbut not digested. The fermentation of prebiotics can
benefit the host by stimulating growth and activity in in-
testinal microbial species. Prebiotics are not absorbed by
the small intestine, and their fermentation allows en-
dogenous bacteria to produce energy and metabolic sub-
strates. So far, the main prebiotics include inulin-type
fructans (ITF) and short-chain fructo-oligosaccharides
(scFOS) [29]. Different studies involving obese women
and gnotobiotic mice have shown that ITF and scFOS
stimulate Bifidobacteria, which benefit the host by redu-
cing intestinal endotoxin concentration and improving
glucose tolerance and inflammation [30,31].Synbiotics
Recently, there have been attempts at using pre- and pro-
biotics simultaneously as treatment. The combination of
pre- and probiotics is a new approach called synbiotics. A
study on elderly fecal microbiota supports the ability of
synbiotics to modulate intestinal flora. The effect of two
prebiotics and two probiotics, both individually and in
synbiotic combinations, were investigated. The synbiotic
combinations were shown to increase the Bifidobacterium
and Lactobacillus count in elderly individuals [32]. Al-
though the study did not try to treat a specific condition,
it shows that synbiotics could be entertained as a possi-
bility for treatment rather than just pre- and probiotics
individually.
In fact, there is currently a clinical trial underway which
will try to treat chronic kidney disease (CKD) with synbio-
tics by targeting uremic toxin synthesis. There have also
been a few clinical trials that have tried to alleviate irrit-
able bowel syndrome (IBS) with synbiotics, and these trials
have shown some promise [29,33]. Otherwise, there is still
limited data on the efficacy and safety of synbiotics for hu-
man diseases.Fecal microbiota transplantation (FMT)
Fecal microbiota transplantation (FMT) is another method
that can be used to treat diseases due to gut microbiota
dysbiosis. Since only 60% of the human microbiota is stable
and durable [34], there is room left for microbiota modula-
tion. Up until now, FMT has mainly been used to treat
Clostridium difficile infection (CDI) with high success. Van
Nood et al. emphasized the effectiveness of FMTcompared
to Vancomycin: FMT was curative for 81% of patients
while Vancomycin, which originated from soil bacteria, was
only effective for 31% [35,36]. It has been hypothesized that
FMT helps with the recovery of a bacteria that can resist
the colonization of C. difficile, but it is not completely clear
exactly how this occurs Another possibility, as shown in a
recent study, is that FMT leads to an increase in secondary
bile salts, suggesting that bile salt metabolism is important
in limiting CDI [37].
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sisted of Proteobacteria, but after FMT, the Proteo-
bacteria count decreased and there is a higher diversity
of Firmicutes and Bacteroidetes [35,37]. It has also been
found that post-FMT, the recipient gut microbiota
composition tends towards that of the donor’s with
a strong representation of Firmicutes, Clostridia, and
Bacilli.
Besides CDI, a study was conducted on the effect of
FMT on patients with chronic active ulcerative colitis
(UC). The aim was to see if UC patients could improve
with FMT and if the microbiotal dysbiosis in UC could
be reversed. Although all the patients experienced short-
term improvement within the first two weeks of FMT,
none of them achieved complete remission or long-term
improvement [34]. Therefore, it was concluded that
microbiotal dysbiosis is only a secondary cause in UC,
unlike in CDI. Furthermore, a separate study involving
mice tried to use FMT to determine whether resistance
to food-borne listeriosis depended on the murine gut
microbiota. It was found that FMT increased neither
susceptibility nor enhancement of listeriosis [30]. These
examples highlight the importance of clarifying which
diseases are caused primarily by microbiotal imbalances,
otherwise FMT may not prove effective.
Although FMT has technically been in practice as a
therapeutic method for millennia, it has only been brought
to medical attention in recent years. Because gut micro-
biotal dysbiosis can contribute to obesity, metabolic syn-
dromes, etc., FMT could put a patient at risk for these
diseases as complications [38]. Despite FMT’s high suc-
cess rate in treating CDI, there is still insufficient data
for wider usage of FMT. Another challenge facing the
use of FMT is that fecal donors must be extensively
screened, which could slow down treatment. Some even
believe that fecal transplants will soon become outdated
after the medical community learns to identify only
the necessary specific microorganisms needed to fight
different diseases [38]. Even though FMT is gaining
in popularity, some safety concerns still remain, and
the US Food and Drug Administration (FDA) requires
an investigational new drug (IND) application for
its use in treating all other gastrointestinal and non-
gastrointestinal diseases [39].
Studies comparing the use of FMT in children and
adults have shown that children treated with FMT
for C. difficile have had restoration of bowel function.
Again, this could simply be due to the nature of C. dif-
ficile being primarily caused by microbiotal dysbiosis of
a specific bacteria. A study showed some efficacy in
treating pediatric UC with FMT; however, with their
study being the first of its kind and with only nine cases
studied, more data would provide confirmation of this
finding.Dietary alterations
The gut microbiota is susceptible to modulation by en-
vironmental factors [34], such as diet. Development of
gut microbiota starts at birth, when the baby is exposed
to a complex array of bacteria in the birth canal. A baby’s
gut microbiota closely resembles its mother’s, as shown by
studies involving mice, and stabilizes at around the age of
one [40]. As time goes on, a child’s initial colonization of
gut microbiota is influenced by diet and, as a result, varies
greatly between individuals. The adaptive nature of gut
microbiota is further supported by another study that
compared fecal samples of children in Europe and rural
Africa. The African children have high-fiber diets due to
reliance on agricultural food sources, while the European
children have diets high in sugar, starch, and fat but
low in fiber. The African children were found to have
high numbers of Bacteroidetes but lacked Firmicutes,
but had an abundance of bacteria from the genus Pre-
votella and Xylanibacter which the European children
lacked completely [41].
Therefore, diet could play a large role in helping to re-
balance gut microbiota. Although diet has been shown
to impact the gut microbiota, more research could be
carried out with regards to what kinds of diets are most
beneficial for different pattern of microbial imbalances
associated with specific conditions.
Conclusion and future outlooks
Although gut microbiota reside in the intestines, its sys-
temic effects are significant. It has become evident that
microbiotal dysbiosis contributes to many of these sys-
temic effects. However, further investigation is needed to
truly clarify whether the relationship between microbio-
tal dysbiosis and diseases is a causal one. For example,
patients with T1DM cannot process glucose and must
maintain special diets, which could lead to altered micro-
biota composition being a consequence rather than a
factor. It is imperative to distinguish between causal ef-
fects, correlations, and consequences when dealing with
gut microbiota and disease, and more work is needed
in this area.
Also, although there exists general information on the
mechanisms and actions of gut microbiota, more in
depth investigation is needed to genuinely understand
its role in specific cases. So far, although a few attempts
at manipulating gut microbiota as therapy have been
met with some success, there are conflicting results
which makes interpretation difficult in arriving at a con-
sensus [25,26,42].
Interest in gut microbiota has increased exponentially in
recent years, with yield of more insights, discoveries, and
revelations than ever before. However, more in depth ex-
ploration in would help to enhance the understanding of
gut microbiota than ever before.
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